Literature DB >> 10739409

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

S Kapur1, R Zipursky, C Jones, G Remington, S Houle.   

Abstract

OBJECTIVE: Since all antipsychotics block dopamine D(2) receptors, the authors investigated how well D(2) receptor occupancy in vivo predicts clinical response, extrapyramidal side effects, and hyperprolactinemia.
METHOD: In a double-blind study, 22 patients with first-episode schizophrenia were randomly assigned to 1.0 or 2. 5 mg/day of haloperidol. After 2 weeks of treatment, D(2) receptor occupancy was determined with [(11)C]raclopride and positron emission tomography, and clinical response, extrapyramidal side effects, and prolactin levels were measured. Patients who showed adequate responses continued taking their initial doses, those who did not respond had their doses increased to 5.0 mg/day, and evaluations were repeated at 4 weeks for all patients.
RESULTS: The patients showed a wide range of D(2) occupancy (38%-87%). The degree of receptor occupancy predicted clinical improvement, hyperprolactinemia, and extrapyramidal side effects. The likelihood of clinical response, hyperprolactinemia, and extrapyramidal side effects increased significantly as D(2) occupancy exceeded 65%, 72%, and 78%, respectively.
CONCLUSIONS: The study confirms that D(2) occupancy is an important mediator of response and side effects in antipsychotic treatment. The data are consistent with a "target and trigger" hypothesis of antipsychotic action, i.e., that the D(2) receptor specificity of antipsychotics permits them to target discrete neurons and that their antagonist properties trigger within those neurons intracellular changes that ultimately beget antipsychotic response. While limited to haloperidol, the relationship between D(2) occupancy and side effects in this study helps explain many of the observed clinical differences between typical and atypical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739409     DOI: 10.1176/appi.ajp.157.4.514

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  243 in total

Review 1.  Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies.

Authors:  J Tauscher; S Kapur
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.

Authors:  Carol J Lane; Elton T C Ngan; Lakshmi N Yatham; Tom J Ruth; Peter F Liddle
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

Review 4.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

5.  Using Atypical Antipsychotics in Primary Care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-12

6.  Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

Authors:  Keisuke Takahata; Hiroshi Ito; Harumasa Takano; Ryosuke Arakawa; Hironobu Fujiwara; Yasuyuki Kimura; Fumitoshi Kodaka; Takeshi Sasaki; Tsuyoshi Nogami; Masayuki Suzuki; Tomohisa Nagashima; Hitoshi Shimada; Motoichiro Kato; Masaru Mimura; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

7.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

8.  Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Jae Min Jeong; Jae Sung Lee; In-Jin Jang; Sang-Goo Shin; Federico E Turkheimer; Shitij Kapur; Jun Soo Kwon
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-21       Impact factor: 6.200

9.  Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Authors:  Sébastien Urben; Pierre Baumann; Sandra Barcellona; Muriel Hafil; Ulrich Preuss; Claire Peter-Favre; Stéphanie Clarke; Olivier Halfon; Laurent Holzer
Journal:  Psychiatr Q       Date:  2012-09

Review 10.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.